# Chest Pain Evaluation â€“ RRT Protocol with Virtua Voorhees Addenda

**Primary Guideline:** American Heart Association/American College of Cardiology (AHA/ACC) 2023 Guidelines for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes
**Official Source:** https://www.ahajournals.org/doi/10.1161/CIR.0000000000001204
**Supporting Guidelines:**
- 2023 ESC Guidelines for the Management of Acute Coronary Syndromes
- 2024 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain
- 2023 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism

## ENHANCED MERMAID FLOWCHART ALGORITHM

~~~mermaid
graph TD
    A["Chest Pain Recognition<br/>RRT Activation"] --> B["ABC Assessment<br/>12-Lead ECG â‰¤10min"]
    
    B --> C{"STEMI<br/>Present?"}
    
    C -->|YES| D["Code STEMI Activation<br/>Transfer to STEMI Protocol"]
    C -->|NO| E["Risk Stratification<br/>HEART Score + Clinical"]
    
    D --> F["Primary PCI Pathway<br/>Door-to-Balloon <90min"]
    E --> G{"High-Risk<br/>Features?"}
    
    G -->|YES| H["Immediate Workup<br/>Serial Troponins + Imaging"]
    G -->|NO| I["Standard Evaluation<br/>Basic Workup"]
    
    H --> J{"Suspected<br/>Diagnosis?"}
    I --> K["Initial Troponin<br/>+ Basic Labs"]
    
    J -->|ACS| L["NSTEACS Protocol<br/>DAPT + Anticoagulation"]
    J -->|PE| M["Wells Score<br/>+ D-Dimer/CTA"]
    J -->|DISSECTION| N["CTA Chest/Abd<br/>Emergent Evaluation"]
    J -->|OTHER| O["Targeted Workup<br/>Based on Presentation"]
    
    K --> P{"Initial Troponin<br/>Elevated?"}
    
    L --> Q["Cardiology Consult<br/>Risk Stratification"]
    M --> R{"PE<br/>Confirmed?"}
    N --> S{"Dissection<br/>Type?"}
    O --> T["Alternative Diagnosis<br/>Management"]
    
    P -->|YES| L
    P -->|NO| U{"HEART Score<br/>â‰¥4?"}
    
    Q --> V{"Invasive Strategy<br/>Indicated?"}
    R -->|YES| W["Anticoagulation<br/>Risk Stratify"]
    R -->|NO| X["Alternative Diagnosis<br/>Consider Other Causes"]
    S -->|"TYPE A"| Y["Emergency Surgery<br/>Immediate OR"]
    S -->|"TYPE B"| Z["Medical Management<br/>BP Control"]
    
    U -->|YES| AA["Serial Troponins<br/>Observation"]
    U -->|NO| BB["Low-Risk Discharge<br/>Outpatient Follow-up"]
    
    V -->|YES| CC["Cardiac Catheterization<br/>Early Invasive"]
    V -->|NO| DD["Conservative Management<br/>Stress Testing"]
    
    AA --> EE{"Serial Troponins<br/>Positive?"}
    EE -->|YES| L
    EE -->|NO| FF["Stress Test<br/>vs Discharge"]
    
    F --> GG["ICU/CCU Admission<br/>Post-PCI Care"]
    CC --> GG
    DD --> HH["Telemetry Admission<br/>Medical Management"]
    W --> HH
    Y --> II["ICU/Post-Op<br/>Surgical Recovery"]
    Z --> II
    BB --> JJ["Discharge Home<br/>PCP Follow-up"]
    FF --> JJ
    T --> KK["Disposition Based<br/>on Final Diagnosis"]
    X --> KK
    
    style A fill:#ffcccc
    style B fill:#ffe6cc
    style D fill:#ffaaaa
    style L fill:#fff2cc
    style Q fill:#ccffcc
    style Y fill:#ff6666
    style GG fill:#ccffee
~~~

## STREAMLINED DYNAMIC CARD SYSTEM

### Card 0 â€“ Chest Pain Recognition & Initial Assessment (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’” CHEST PAIN RRT ACTIVATION            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Recognition criteria:                â”‚
â”‚ â€¢ Chest pain/discomfort                â”‚
â”‚ â€¢ Chest pressure/tightness             â”‚
â”‚ â€¢ Epigastric pain (ACS equivalent)      â”‚
â”‚ â€¢ Arm/jaw pain without chest pain      â”‚
â”‚ â€¢ Dyspnea with chest symptoms          â”‚
â”‚                                         â”‚
â”‚ ğŸš¨ ABC Assessment (Priority #1):        â”‚
â”‚ â€¢ Airway: Patent and protected         â”‚
â”‚ â€¢ Breathing: Adequate ventilation      â”‚
â”‚ â€¢ Circulation: Perfusion assessment    â”‚
â”‚ â€¢ Disability: Neurologic status        â”‚
â”‚                                         â”‚
â”‚ âš¡ Time-critical actions:               â”‚
â”‚ â€¢ 12-lead ECG within 10 minutes        â”‚
â”‚ â€¢ IV access establishment              â”‚
â”‚ â€¢ Continuous cardiac monitoring        â”‚
â”‚ â€¢ Vital signs with bilateral BP        â”‚
â”‚                                         â”‚
â”‚ [Next: ECG interpretation â–¶]           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1A â€“ STEMI Protocol Activation (Node D â†’ F)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ STEMI IDENTIFIED - CODE ACTIVATION    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š STEMI criteria confirmed:            â”‚
â”‚ â€¢ ST-elevation â‰¥1mm in â‰¥2 contiguous leadsâ”‚
â”‚ â€¢ New LBBB with clinical correlation   â”‚
â”‚ â€¢ Posterior STEMI equivalent           â”‚
â”‚                                         â”‚
â”‚ ğŸ”— Protocol transition:                 â”‚
â”‚ â€¢ [TRANSFER TO CODE STEMI PROTOCOL]    â”‚
â”‚ â€¢ Activate cath lab team               â”‚
â”‚ â€¢ Transfer Center: 856-886-5111        â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Immediate medications:               â”‚
â”‚ â€¢ Aspirin 324mg chewed                 â”‚
â”‚ â€¢ Ticagrelor 180mg loading dose        â”‚
â”‚ â€¢ Heparin per STEMI protocol           â”‚
â”‚                                         â”‚
â”‚ â±ï¸ Time targets:                        â”‚
â”‚ â€¢ Door-to-balloon <90 minutes          â”‚
â”‚ â€¢ STEMI protocol activation            â”‚
â”‚                                         â”‚
â”‚ âœ… CODE STEMI PROTOCOL ACTIVE          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: ECG Recognition]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1B â€“ Risk Stratification (Node E â†’ G)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“Š CHEST PAIN RISK STRATIFICATION       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ HEART Score calculation (2024 update):â”‚
â”‚ â€¢ History: Highly/moderately/low susp  â”‚
â”‚ â€¢ ECG: ST depression/LBBB/Normal       â”‚
â”‚ â€¢ Age: â‰¥65, 45-64, <45 years           â”‚
â”‚ â€¢ Risk factors: â‰¥3, 1-2, 0 factors     â”‚
â”‚ â€¢ Troponin: >3Ã—, 1-3Ã—, <1Ã— normal     â”‚
â”‚                                         â”‚
â”‚ ğŸš¨ High-risk features (any present):    â”‚
â”‚ â€¢ Hemodynamic instability             â”‚
â”‚ â€¢ Persistent symptoms >20 minutes      â”‚
â”‚ â€¢ Dynamic ECG changes                  â”‚
â”‚ â€¢ Known CAD with recent symptoms       â”‚
â”‚ â€¢ Diabetes + typical symptoms          â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Additional risk factors:             â”‚
â”‚ â€¢ Family history of early CAD         â”‚
â”‚ â€¢ Smoking, hypertension, dyslipidemia â”‚
â”‚ â€¢ Prior revascularization              â”‚
â”‚                                         â”‚
â”‚ [Next: Risk level determination â–¶]     â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: ECG Interpretation]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ High-Risk Immediate Workup (Node H â†’ J)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ HIGH-RISK IMMEDIATE EVALUATION       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š STAT laboratory studies:             â”‚
â”‚ â€¢ High-sensitivity troponin I/T        â”‚
â”‚ â€¢ Complete blood count                 â”‚
â”‚ â€¢ Basic metabolic panel                â”‚
â”‚ â€¢ PT/INR, PTT                          â”‚
â”‚ â€¢ Lipid panel                          â”‚
â”‚                                         â”‚
â”‚ ğŸ“¸ Immediate imaging:                   â”‚
â”‚ â€¢ Portable chest X-ray                â”‚
â”‚ â€¢ Consider bedside echocardiogram      â”‚
â”‚ â€¢ CT imaging if dissection suspected   â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Initial treatment:                   â”‚
â”‚ â€¢ Aspirin 324mg chewed if not given    â”‚
â”‚ â€¢ Nitroglycerin 0.4mg SL PRN pain      â”‚
â”‚ â€¢ Morphine 2-4mg IV PRN (Class IIb)    â”‚
â”‚                                         â”‚
â”‚ [Next: Suspected diagnosis â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Risk Stratification]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2B â€“ Standard Evaluation (Node I â†’ K)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“‹ STANDARD CHEST PAIN EVALUATION       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Basic laboratory studies:            â”‚
â”‚ â€¢ High-sensitivity troponin (baseline) â”‚
â”‚ â€¢ Complete blood count                 â”‚
â”‚ â€¢ Basic metabolic panel                â”‚
â”‚ â€¢ Consider D-dimer if PE risk          â”‚
â”‚                                         â”‚
â”‚ ğŸ“¸ Basic imaging:                       â”‚
â”‚ â€¢ Portable chest X-ray                â”‚
â”‚ â€¢ Additional imaging based on suspicionâ”‚
â”‚                                         â”‚
â”‚ ğŸ“ Focused history elements:            â”‚
â”‚ â€¢ Pain character, duration, radiation  â”‚
â”‚ â€¢ Associated symptoms                  â”‚
â”‚ â€¢ Previous cardiac history             â”‚
â”‚ â€¢ Risk factors assessment              â”‚
â”‚                                         â”‚
â”‚ [Next: Initial troponin result â–¶]      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Risk Stratification]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3A â€“ NSTEACS Protocol (Node L â†’ Q)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’” NON-ST ELEVATION ACS PROTOCOL        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Dual antiplatelet therapy (2023 update):â”‚
â”‚ â€¢ Aspirin 81mg daily (after loading)   â”‚
â”‚ â€¢ Ticagrelor 90mg BID (preferred)      â”‚
â”‚ â€¢ Or clopidogrel 75mg daily           â”‚
â”‚ â€¢ Or prasugrel 10mg daily (if PCI planned)â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Anticoagulation (choose one):        â”‚
â”‚ â€¢ UFH: 60 units/kg bolus â†’ 12 units/kg/hrâ”‚
â”‚ â€¢ Enoxaparin: 1mg/kg SC BID            â”‚
â”‚ â€¢ Fondaparinux: 2.5mg SC daily         â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Additional therapies:                â”‚
â”‚ â€¢ High-intensity statin (atorvastatin 80mg)â”‚
â”‚ â€¢ Beta-blocker (if no contraindications)â”‚
â”‚ â€¢ ACE inhibitor (if LV dysfunction)    â”‚
â”‚                                         â”‚
â”‚ [Next: Cardiology consultation â–¶]      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Suspected Diagnosis]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3B â€“ Pulmonary Embolism Evaluation (Node M â†’ R)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ« PULMONARY EMBOLISM ASSESSMENT        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Wells Score calculation (2023 update):â”‚
â”‚ â€¢ Clinical signs of DVT (3 points)     â”‚
â”‚ â€¢ PE most likely diagnosis (3 points)  â”‚
â”‚ â€¢ Heart rate >100 bpm (1.5 points)     â”‚
â”‚ â€¢ Immobilization/surgery (1.5 points)  â”‚
â”‚ â€¢ Previous PE/DVT (1.5 points)         â”‚
â”‚ â€¢ Hemoptysis (1 point)                 â”‚
â”‚ â€¢ Malignancy (1 point)                 â”‚
â”‚                                         â”‚
â”‚ ğŸ”¬ Diagnostic strategy:                 â”‚
â”‚ â€¢ Wells <2: D-dimer first              â”‚
â”‚ â€¢ Wells â‰¥2: Consider CTA chest         â”‚
â”‚ â€¢ Age-adjusted D-dimer (Age Ã— 10 ng/mL)â”‚
â”‚                                         â”‚
â”‚ ğŸ“¸ Imaging options:                     â”‚
â”‚ â€¢ CTPA (CT pulmonary angiogram)        â”‚
â”‚ â€¢ V/Q scan if contrast contraindicated â”‚
â”‚                                         â”‚
â”‚ [Next: PE confirmation â–¶]              â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Suspected Diagnosis]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3C â€“ Aortic Dissection Evaluation (Node N â†’ S)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ©¸ AORTIC DISSECTION ASSESSMENT         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš¨ High-risk features:                  â”‚
â”‚ â€¢ Tearing/ripping chest/back pain      â”‚
â”‚ â€¢ Pulse deficit or BP differential >20mmHgâ”‚
â”‚ â€¢ Acute aortic regurgitation murmur    â”‚
â”‚ â€¢ Mediastinal widening on CXR          â”‚
â”‚                                         â”‚
â”‚ ğŸ“¸ Immediate imaging:                   â”‚
â”‚ â€¢ CTA chest/abdomen/pelvis with contrastâ”‚
â”‚ â€¢ TEE if hemodynamically unstable      â”‚
â”‚ â€¢ Avoid delay for "rule-out" testing   â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Blood pressure management:           â”‚
â”‚ â€¢ Target SBP 100-120 mmHg              â”‚
â”‚ â€¢ Beta-blocker first (esmolol preferred)â”‚
â”‚ â€¢ Then vasodilator if needed           â”‚
â”‚ â€¢ AVOID anticoagulation               â”‚
â”‚                                         â”‚
â”‚ [Next: Type classification â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Suspected Diagnosis]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4A â€“ Cardiology Consultation (Node Q â†’ V)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’¼ CARDIOLOGY CONSULTATION              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ Consultation timing:                 â”‚
â”‚ â€¢ STAT: Unstable ACS, cardiogenic shockâ”‚
â”‚ â€¢ Urgent: NSTEMI, high-risk NSTEACS    â”‚
â”‚ â€¢ Routine: Stable angina evaluation    â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Risk stratification (GRACE 2.0 score):â”‚
â”‚ â€¢ Age, heart rate, systolic BP         â”‚
â”‚ â€¢ Creatinine, Killip class             â”‚
â”‚ â€¢ Cardiac arrest, ST deviation         â”‚
â”‚ â€¢ Elevated cardiac biomarkers          â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Invasive strategy decision:          â”‚
â”‚ â€¢ Early invasive (<24h): High-risk     â”‚
â”‚ â€¢ Selective invasive: Intermediate-riskâ”‚
â”‚ â€¢ Conservative: Low-risk, stable       â”‚
â”‚                                         â”‚
â”‚ [Next: Invasive strategy decision â–¶]   â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: NSTEACS Protocol]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4B â€“ PE Confirmation & Treatment (Node R)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âœ… PULMONARY EMBOLISM MANAGEMENT        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ â“ PE confirmed on imaging?             â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Anticoagulation protocol:     â”‚
â”‚ â€¢ UFH: 80 units/kg bolus â†’ 18 units/kg/hrâ”‚
â”‚ â€¢ Or LMWH: Enoxaparin 1mg/kg SC BID    â”‚
â”‚ â€¢ Or DOAC: Apixaban/rivaroxaban        â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Severity assessment:                 â”‚
â”‚ â€¢ Massive PE: Hemodynamic instability  â”‚
â”‚ â€¢ Submassive PE: RV strain without shockâ”‚
â”‚ â€¢ Low-risk PE: No RV strain            â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Thrombolysis consideration:          â”‚
â”‚ â€¢ Massive PE with shock                â”‚
â”‚ â€¢ Selected submassive PE cases         â”‚
â”‚ â€¢ Alteplase 100mg IV over 2 hours      â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ NO â†’ Alternative diagnosis workup   â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4C â€“ Dissection Type Classification (Node S)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ©¸ AORTIC DISSECTION TYPE CLASSIFICATIONâ”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Stanford Classification:             â”‚
â”‚                                         â”‚
â”‚ ğŸ”´ Type A (Ascending aorta):            â”‚
â”‚ â€¢ Involves ascending aorta             â”‚
â”‚ â€¢ Surgical emergency                   â”‚
â”‚ â€¢ Mortality 1-2% per hour if untreated â”‚
â”‚                                         â”‚
â”‚ ğŸ”µ Type B (Descending aorta):           â”‚
â”‚ â€¢ Does not involve ascending aorta     â”‚
â”‚ â€¢ Medical management preferred         â”‚
â”‚ â€¢ Surgery for complications           â”‚
â”‚                                         â”‚
â”‚ â“ Dissection type identified?          â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ TYPE A â†’ Emergency surgery          â”‚
â”‚ ğŸ”˜ TYPE B â†’ Medical management         â”‚
â”‚                                         â”‚
â”‚ ğŸ“ Immediate consultations:             â”‚
â”‚ â€¢ Cardiothoracic surgery (Type A)      â”‚
â”‚ â€¢ Vascular surgery (complicated Type B)â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5A â€“ Initial Troponin Evaluation (Node P)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ§ª INITIAL TROPONIN INTERPRETATION      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š High-sensitivity troponin (2024 update):â”‚
â”‚ â€¢ 99th percentile upper reference limitâ”‚
â”‚ â€¢ Sex-specific cutoffs recommended     â”‚
â”‚ â€¢ Optimal sampling: 0 and 1-2 hours    â”‚
â”‚                                         â”‚
â”‚ â“ Initial troponin elevated?           â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ NSTEACS protocol activation:  â”‚
â”‚ â€¢ Treat as NSTEMI                      â”‚
â”‚ â€¢ Begin dual antiplatelet therapy      â”‚
â”‚ â€¢ Anticoagulation                      â”‚
â”‚ â€¢ Cardiology consultation              â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ NO â†’ HEART score assessment:        â”‚
â”‚ â€¢ Calculate updated HEART score        â”‚
â”‚ â€¢ Determine observation vs discharge   â”‚
â”‚ â€¢ Serial troponins if indicated        â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5B â€“ HEART Score Decision (Node U)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’” HEART SCORE RISK STRATIFICATION      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š HEART Score interpretation (2024):   â”‚
â”‚ â€¢ 0-3 points: Low risk (1.7% MACE)     â”‚
â”‚ â€¢ 4-6 points: Intermediate (12% MACE)  â”‚
â”‚ â€¢ 7-10 points: High risk (65% MACE)    â”‚
â”‚                                         â”‚
â”‚ â“ HEART Score â‰¥4 points?               â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Serial troponins required:    â”‚
â”‚ â€¢ q6h Ã— 2-3 sets minimum               â”‚
â”‚ â€¢ Admit for observation               â”‚
â”‚ â€¢ Consider stress testing              â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ NO â†’ Low-risk discharge eligible:   â”‚
â”‚ â€¢ Single negative troponin sufficient â”‚
â”‚ â€¢ Discharge with cardiology follow-up â”‚
â”‚ â€¢ Return precautions provided          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6A â€“ Early Invasive Strategy (Node CC â†’ GG)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âš¡ EARLY INVASIVE CATHETERIZATION       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Indications for early invasive (<24h):â”‚
â”‚ â€¢ Refractory ischemia                  â”‚
â”‚ â€¢ Recurrent ischemia with treatment    â”‚
â”‚ â€¢ High-risk troponin pattern           â”‚
â”‚ â€¢ Hemodynamic instability              â”‚
â”‚ â€¢ Sustained VT/VF                      â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Pre-catheterization optimization:    â”‚
â”‚ â€¢ Optimize DAPT (ticagrelor preferred) â”‚
â”‚ â€¢ Hold heparin 4-6h before procedure  â”‚
â”‚ â€¢ Continue statin therapy              â”‚
â”‚                                         â”‚
â”‚ ğŸ¥ Post-procedure care:                 â”‚
â”‚ â€¢ ICU/CCU monitoring                   â”‚
â”‚ â€¢ Bleeding surveillance                â”‚
â”‚ â€¢ Medication reconciliation            â”‚
â”‚                                         â”‚
â”‚ [Next: ICU/CCU admission â–¶]            â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Invasive Strategy Decision]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6B â€“ Conservative Management (Node DD â†’ HH)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ›¡ï¸ CONSERVATIVE MEDICAL MANAGEMENT      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Optimal medical therapy:             â”‚
â”‚ â€¢ Continue DAPT regimen                â”‚
â”‚ â€¢ High-intensity statin                â”‚
â”‚ â€¢ Beta-blocker optimization            â”‚
â”‚ â€¢ ACE inhibitor if indicated           â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Risk stratification:                 â”‚
â”‚ â€¢ Stress testing (exercise or pharmacologic)â”‚
â”‚ â€¢ Echocardiogram for LV function       â”‚
â”‚ â€¢ Consider CTA coronaries if appropriateâ”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Discharge planning:                  â”‚
â”‚ â€¢ Medication education                 â”‚
â”‚ â€¢ Lifestyle modifications              â”‚
â”‚ â€¢ Cardiology follow-up in 1-2 weeks    â”‚
â”‚                                         â”‚
â”‚ [Next: Telemetry admission â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Invasive Strategy Decision]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7A â€“ Emergency Surgery (Node Y â†’ II)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”ª EMERGENCY AORTIC SURGERY (TYPE A)    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš¨ Immediate surgical consultation:     â”‚
â”‚ â€¢ Cardiothoracic surgery STAT          â”‚
â”‚ â€¢ Operating room preparation           â”‚
â”‚ â€¢ Anesthesia team activation           â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Pre-operative management:            â”‚
â”‚ â€¢ Continue blood pressure control      â”‚
â”‚ â€¢ Avoid anticoagulation               â”‚
â”‚ â€¢ Type and crossmatch 6+ units        â”‚
â”‚ â€¢ Central line and arterial line       â”‚
â”‚                                         â”‚
â”‚ â±ï¸ Time-critical priorities:            â”‚
â”‚ â€¢ Surgery within 6 hours optimal       â”‚
â”‚ â€¢ Mortality increases with delay       â”‚
â”‚ â€¢ Operating room takes priority        â”‚
â”‚                                         â”‚
â”‚ [Next: ICU post-operative care â–¶]      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Type A Classification]    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7B â€“ Serial Troponin Monitoring (Node AA â†’ EE)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ˆ SERIAL TROPONIN MONITORING           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ â±ï¸ Sampling protocol (2024 guidelines):  â”‚
â”‚ â€¢ Baseline (0 hours)                   â”‚
â”‚ â€¢ 1-2 hours (high-sensitivity optimal) â”‚
â”‚ â€¢ 6 hours (if initial negative)        â”‚
â”‚ â€¢ Additional if symptoms recur          â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Interpretation criteria:             â”‚
â”‚ â€¢ Rising pattern: Suggests acute MI    â”‚
â”‚ â€¢ Falling pattern: Prior infarction    â”‚
â”‚ â€¢ Delta change: >20% considered significantâ”‚
â”‚                                         â”‚
â”‚ ğŸ”„ Monitoring during observation:       â”‚
â”‚ â€¢ Continuous telemetry                 â”‚
â”‚ â€¢ Symptom assessment q4h               â”‚
â”‚ â€¢ Vital signs per protocol             â”‚
â”‚                                         â”‚
â”‚ [Next: Final troponin decision â–¶]      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: HEART Score Assessment]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 8A â€“ Low-Risk Discharge (Node BB â†’ JJ)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ  LOW-RISK DISCHARGE PROTOCOL          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âœ… Discharge criteria met:              â”‚
â”‚ â€¢ HEART score <4                       â”‚
â”‚ â€¢ Negative troponin                    â”‚
â”‚ â€¢ Pain resolved or improved            â”‚
â”‚ â€¢ Stable vital signs                   â”‚
â”‚ â€¢ No high-risk features                â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Discharge medications:               â”‚
â”‚ â€¢ Aspirin 81mg daily                   â”‚
â”‚ â€¢ Consider statin if risk factors      â”‚
â”‚ â€¢ Nitroglycerin SL PRN (if indicated)  â”‚
â”‚                                         â”‚
â”‚ ğŸ“ Follow-up arrangements:              â”‚
â”‚ â€¢ Primary care within 1 week           â”‚
â”‚ â€¢ Cardiology if recurrent symptoms     â”‚
â”‚ â€¢ Return precautions provided          â”‚
â”‚                                         â”‚
â”‚ ğŸ“š Patient education:                   â”‚
â”‚ â€¢ When to seek emergency care          â”‚
â”‚ â€¢ Lifestyle modifications              â”‚
â”‚ â€¢ Medication compliance                â”‚
â”‚                                         â”‚
â”‚ âœ… DISCHARGE PROTOCOL COMPLETE         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Risk Assessment]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 8B â€“ Stress Testing Protocol (Node FF â†’ JJ)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸƒ STRESS TESTING EVALUATION            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Stress test selection:               â”‚
â”‚ â€¢ Exercise ECG: Young, low-risk patientsâ”‚
â”‚ â€¢ Exercise echo: Intermediate risk      â”‚
â”‚ â€¢ Pharmacologic stress: Unable to exerciseâ”‚
â”‚ â€¢ Nuclear stress: Intermediate-high riskâ”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Timing considerations:               â”‚
â”‚ â€¢ Inpatient: Before discharge if stableâ”‚
â”‚ â€¢ Outpatient: Within 72 hours         â”‚
â”‚ â€¢ Emergency: Within 6 hours if very low riskâ”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Pre-test optimization:               â”‚
â”‚ â€¢ Hold beta-blockers if exercise test  â”‚
â”‚ â€¢ Continue aspirin                     â”‚
â”‚ â€¢ NPO if pharmacologic stress          â”‚
â”‚                                         â”‚
â”‚ [Next: Discharge planning â–¶]           â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Serial Troponin Result]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9 â€“ Disposition Planning (Nodes GG, HH, II, JJ, KK - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ FINAL DISPOSITION & FOLLOW-UP        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ Disposition options:                 â”‚
â”‚                                         â”‚
â”‚ ğŸ”´ ICU/CCU admission:                   â”‚
â”‚ â€¢ Post-catheterization monitoring      â”‚
â”‚ â€¢ Hemodynamic instability             â”‚
â”‚ â€¢ Mechanical complications             â”‚
â”‚ â€¢ Post-surgical aortic dissection      â”‚
â”‚                                         â”‚
â”‚ ğŸŸ¡ Telemetry admission:                 â”‚
â”‚ â€¢ NSTEACS medical management           â”‚
â”‚ â€¢ Serial troponin monitoring          â”‚
â”‚ â€¢ PE anticoagulation                   â”‚
â”‚ â€¢ Type B dissection monitoring         â”‚
â”‚                                         â”‚
â”‚ ğŸŸ¢ Discharge home:                      â”‚
â”‚ â€¢ Low-risk chest pain                  â”‚
â”‚ â€¢ Negative cardiac workup              â”‚
â”‚ â€¢ Alternative diagnosis with treatment â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Follow-up coordination:              â”‚
â”‚ â€¢ Cardiology: 1-2 weeks for ACS        â”‚
â”‚ â€¢ Primary care: Within 1 week          â”‚
â”‚ â€¢ Specialist referrals as indicated    â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Quality metrics documentation:       â”‚
â”‚ â€¢ Door-to-ECG time                     â”‚
â”‚ â€¢ Appropriate DAPT initiation          â”‚
â”‚ â€¢ Risk stratification completion       â”‚
â”‚                                         â”‚
â”‚ âœ… CHEST PAIN PROTOCOL COMPLETE        â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Treatment Completion]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## VIRTUA VOORHEES CHEST PAIN ADDENDA

### **Enhanced RRT Response Program:**
- **Rapid Response Team:** Immediate multidisciplinary activation including cardiology access
- **ECG Integration:** 12-lead capability on all RRT carts with immediate interpretation
- **Laboratory Integration:** High-sensitivity troponin available 24/7 with <60 minute turnaround
- **Quality Metrics:** Door-to-ECG times, appropriate risk stratification, DAPT initiation rates

### **Updated 2023-2024 Guidelines Integration:**
**AHA/ACC 2023 NSTEACS Guidelines:**
- **High-sensitivity troponin protocols:** 0/1h and 0/2h algorithms for rapid rule-out
- **HEART score validation:** Updated risk categories with 2024 meta-analysis data
- **P2Y12 inhibitor selection:** Ticagrelor preferred over clopidogrel for most patients
- **Early invasive strategy:** Refined criteria based on GRACE 2.0 score >140

**ESC 2023 Updates:**
- **0/1h algorithm:** For high-sensitivity troponin with validated cutoffs
- **EDACS pathway:** Emergency Department Assessment of Chest pain Score integration
- **RAPID-TnT protocol:** Ultra-early discharge for very low-risk patients

### **High-Sensitivity Troponin Integration:**
**Abbott ARCHITECT hs-cTnI (Virtua system):**
- **99th percentile:** Males 34.2 ng/L, Females 15.6 ng/L
- **Rule-out cutoff:** <5 ng/L at presentation
- **Rule-in cutoff:** >52 ng/L males, >16 ng/L females
- **Delta criteria:** >50% change in 1 hour or >20% change in 2-6 hours

**Clinical Decision Pathways:**
- **0/1h protocol:** Validated for patients presenting >2h after symptom onset
- **Serial sampling:** q6h Ã— 3 for intermediate-risk patients
- **Peak timing:** Consider 12-24h sampling for late presenters

### **Point-of-Care Integration:**
**Bedside Echocardiography:**
- **Wall motion assessment:** Regional wall motion abnormalities
- **LV function:** Ejection fraction estimation
- **Complications:** Pericardial effusion, mechanical complications
- **RV strain:** Signs of pulmonary embolism

**POCUS Applications:**
- **IVC assessment:** Volume status in heart failure
- **Lung ultrasound:** B-lines for pulmonary edema
- **Aortic root:** Limited assessment for dissection

### **Advanced Risk Stratification:**
**HEART Score (2024 Validation):**
- **Score 0-3:** 6-week MACE 1.7% (safe discharge)
- **Score 4-6:** 6-week MACE 12% (observation/testing)
- **Score 7-10:** 6-week MACE 65% (invasive strategy)

**GRACE 2.0 Score Integration:**
- **In-hospital death risk:** <1%, 1-3%, >3%
- **6-month death/MI risk:** <3%, 3-8%, >8%
- **Invasive strategy:** Recommended if >140 points

### **Medication Protocols - Updated 2024:**
**Dual Antiplatelet Therapy:**
- **Aspirin:** 324mg loading, then 81mg daily
- **Ticagrelor:** 180mg loading, then 90mg BID (preferred)
- **Prasugrel:** 60mg loading, then 10mg daily (avoid if >75y, <60kg, prior stroke)
- **Clopidogrel:** 600mg loading, then 75mg daily (high bleeding risk)

**Anticoagulation Selection:**
- **UFH:** 60 units/kg bolus (max 4000), then 12 units/kg/h (max 1000)
- **Enoxaparin:** 1mg/kg SC BID (preferred if conservative strategy)
- **Fondaparinux:** 2.5mg SC daily (lowest bleeding risk)

### **Emergency Consultation Pathways:**
**Interventional Cardiology:**
- **STEMI:** Direct activation via Code STEMI protocol
- **High-risk NSTEACS:** <24h invasive strategy
- **Cardiogenic shock:** Emergency mechanical support

**Cardiothoracic Surgery:**
- **Type A dissection:** Emergency consultation within 30 minutes
- **Mechanical complications:** Papillary muscle rupture, VSD, free wall rupture
- **Refractory ischemia:** Emergency CABG consideration

### **Quality Improvement Metrics:**
**Process Measures:**
- **Door-to-ECG time:** Goal <10 minutes, target <5 minutes
- **Troponin turnaround:** Goal <60 minutes for high-sensitivity assays
- **DAPT initiation:** >95% for confirmed ACS within 24 hours
- **Risk stratification:** HEART score documentation >90%

**Outcome Measures:**
- **30-day MACE:** Death, MI, urgent revascularization
- **Discharge appropriateness:** Low-risk patients discharged <24h
- **Readmission rates:** 7-day and 30-day cardiac readmissions
- **Patient satisfaction:** ED/chest pain unit experience scores

### **Integration with Other Protocols:**
- **Code STEMI:** Seamless transition for ST-elevation cases
- **Shock Protocol:** For cardiogenic shock management
- **Atrial Fibrillation:** For rate control in RVR
- **Acute Heart Failure:** For decompensated CHF presentations

### **Special Population Considerations:**
**Diabetic Patients:**
- **Atypical presentations:** Higher index of suspicion
- **Silent ischemia:** Lower pain thresholds
- **Aggressive risk factor modification:** Statin and ACE inhibitor therapy

**Elderly Patients (>75 years):**
- **Bleeding risk assessment:** HAS-BLED score integration
- **Medication adjustments:** Reduced prasugrel dosing
- **Functional status:** Consider goals of care discussions

**Women:**
- **Atypical presentations:** Jaw pain, nausea, fatigue without chest pain
- **Microvascular disease:** Consider despite normal coronaries
- **Pregnancy considerations:** Avoid ACE inhibitors and statins

**Chronic Kidney Disease:**
- **Contrast nephropathy prevention:** Hydration protocols
- **Medication dosing:** Renally-adjusted anticoagulation
- **Troponin interpretation:** Baseline elevation considerations

### **Discharge Planning & Follow-up:**
**Medication Reconciliation:**
- **DAPT duration:** Minimum 12 months for ACS
- **Statin therapy:** High-intensity for secondary prevention
- **Beta-blocker optimization:** Titrate to heart rate 50-60 bpm
- **ACE inhibitor/ARB:** For LV dysfunction or diabetes

**Lifestyle Counseling:**
- **Smoking cessation:** Pharmacotherapy and counseling referrals
- **Cardiac rehabilitation:** Referral within 30 days
- **Dietary counseling:** Mediterranean diet recommendations
- **Exercise prescription:** Structured activity recommendations

## REFERENCE GUIDELINES
- **2023 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes**
- **2024 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain**
- **2023 ESC Guidelines for the Management of Acute Coronary Syndromes**
- **2023 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism**
- **Virtua Health System Chest Pain Protocol v2025**

**This comprehensive protocol integrates the latest evidence-based chest pain evaluation with rapid diagnostic capabilities, advanced risk stratification, and seamless integration with cardiac interventional services optimized for excellent patient outcomes at Virtua Voorhees.**
